Claims for Patent: 7,825,246

Summary for Patent: 7,825,246

Title:	Bi-aryl meta-pyrimidine inhibitors of kinases
Abstract:	The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
Inventor(s):	Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
Assignee:	Impact Therapeutics Inc, Impact Biomedicines Inc
Application Number:	US11/796,717
Patent Claims:	1. A compound having the structure (B): wherein: X is selected from a group consisting of a bond, O, C═O, SO2, and CH2; Y is selected from a group consisting of a bond and NR9; or X and Y taken together is a bond; R9 is selected from a group consisting of H, C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 branched alkyl, C1-C6 aminoalkyl, and C1-C6 hydroxyalkyl; each of R1 is independently selected from a group consisting of H, C1-C6 alkyl, cycloalkyl, and heterocycle; each of n, or p is independently an integer having the value between 0 and 6; Q1 is a 4-7 membered heterocycle connected through carbon or nitrogen, with one or more heteroatoms in the heterocyle, and each carbon or nitrogen in the heterocycle is optionally substituted independently with C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 hydroxyalkyl or aminoalkyl, C1-C6 branched alkyl, C1-C6 cycloalkyl, aryl connected through carbon or a heteroatom, a halogen, CF3, —OCF3, NO2, CN, OH, CONR3R4, and COR3; each of R6, R7, R8 is independently selected from a group consisting of H, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 hydroxyalkyl or aminoalkyl, C1-C6 branched alkyl, C1-C6 cycloalkyl, aryl, C1-C6 alkoxy, a halogen, CF3, —OCF3, CHR3R4, SR3, SOR3, SO2R3, SO2NR3R4, SO3R3, POR3, PO2R3, PO2NR3R4, PO2CR3R4, PO3R3, NR3R4, NO2, CN, OH, CONR3R4, COR3, COOR3, NR3COR4, NR3CONR3R4, OCONR3R4, CSNR3R4, CSR3, NR3CSNR3R4, SCONR3R4, and SCSNR3R4; or any of R6 and R7 taken together, or R7 and R8 taken together, or R6 and R8 taken together form a moiety independently selected from a group consisting of —HN—CH═CH—, —HN—N═CH—, —HN—N═N—, —O(CH2)nO—, —S(CH2)nS—, —N═CH—S—, —CH═N—O—, —CH═N—S—, —N═CH—O—, —C═N—O—, —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, —O—CH═CH—, and —S—CH═CH—; each of R3 and R4 is independently selected from a group consisting of H, C1-C6 alkyl, C1-C6 hydroxyalkyl or aminoalkyl, and C1-C6 branched alkyl, with the further provisos that: (a) at least one of R6, R7 and R8 is not hydrogen; (b) R6 and R7, or R6 and R8, or R7 and R8 are substituted with non-hydrogen atoms, or if only one of R6, R7 and R8 is substituted, then the substitution contains at least three non-hydrogen atoms; (c) any one of R6, R7 or R8 optionally comprises a heteroatom selected from a group consisting of O, N and S; and (d) the moiety Q1 excludes hetero-aromatic cyclic rings, or a pharmaceutically acceptable salt, or an individual diastereomer of the compound (B). 2. The compound of claim 1, having the structure (C): 3. The compound of claim 1 having the structure (D): wherein the moiety attached to a connection point shown in structure (D) is selected from a group consisting of: 4. The compound of claim 1, having the structure (E): 5. The compound of claim 1, having the structure (F): wherein the moiety attached to a connection point shown in structure (F) is selected from a group consisting of: 6. The compound of claim 1, having the structure (G): 7. The compound of claim 1, having the structure (H): wherein the moiety attached to a connection point shown in structure (H) is selected from a group consisting of: 8. The compound of claim 1, having the structure (I): wherein the moiety attached to a connection point shown in structure (H) is selected from a group consisting of: 9. The compound of claim 1, having the structure (J): wherein the moiety attached to a connection point shown in structure (J) is